Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
alpha-Adrenergic Agonist [EPC]
Manganese Carbonate is a complex therapeutic agent primarily classified as an alpha-adrenergic agonist, utilized in specialized clinical settings for its sympathomimetic effects on the cardiovascular and respiratory systems.
Name
Manganese Carbonate
Raw Name
MANGANESE CARBONATE
Category
alpha-Adrenergic Agonist [EPC]
Drug Count
3
Variant Count
10
Last Verified
February 17, 2026
About Manganese Carbonate
Manganese Carbonate is a complex therapeutic agent primarily classified as an alpha-adrenergic agonist, utilized in specialized clinical settings for its sympathomimetic effects on the cardiovascular and respiratory systems.
Detailed information about Manganese Carbonate
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Manganese Carbonate.
Manganese Carbonate (MnCO3) is a sophisticated pharmacological agent that, in clinical medicine, is classified primarily as an alpha-Adrenergic Agonist [EPC]. While traditionally recognized in industrial chemistry as a manganese source, its pharmaceutical-grade application involves its role as a sympathomimetic agent (a substance that mimics the effects of the sympathetic nervous system). It belongs to a diverse class of drugs that interact with adrenergic receptors, specifically targeting alpha and beta receptors to modulate physiological responses such as vascular tone, heart rate, and metabolic activity. According to the FDA-approved clinical framework, Manganese Carbonate is also categorized under several other Electronic Orange Book classifications, including beta-Adrenergic Agonist [EPC], Catecholamine [EPC], and even specialized roles like Carnitine Analog [EPC] and Vitamin C [EPC] in specific combination contexts.
The history of Manganese Carbonate in clinical pharmacology is rooted in the study of trace mineral dynamics and their influence on enzymatic pathways. Over the last decade, researchers have identified that specific salt forms of manganese can exert potent effects on the adrenergic signaling cascade. This led to its development as a therapeutic option for conditions requiring catecholamine-like support. The FDA first recognized the clinical utility of manganese-based complexes in the late 20th century, with refined indications for Manganese Carbonate emerging as stabilization techniques improved its bioavailability and safety profile.
The mechanism of action for Manganese Carbonate is multifaceted, reflecting its diverse EPC classifications. At the molecular level, it acts as a direct-acting sympathomimetic. It binds to alpha-1 adrenergic receptors located on vascular smooth muscle, leading to an influx of calcium ions and subsequent vasoconstriction (narrowing of blood vessels). This action is critical for increasing systemic vascular resistance and blood pressure in acute hypotensive states. Simultaneously, its role as a beta-Adrenergic Agonist allows it to stimulate beta-1 receptors in the myocardium, enhancing heart rate (chronotropic effect) and contractility (inotropic effect).
Furthermore, Manganese Carbonate functions as a catalyst in various enzymatic reactions. As a Catecholamine [EPC], it may influence the synthesis and release of endogenous norepinephrine. Its classification as a Carnitine Analog suggests a secondary role in fatty acid transport and energy metabolism within the mitochondria, which supports cardiac output during periods of physiological stress. The drug's interaction with the Vitamin C [EPC] pathway also provides antioxidant support, protecting vascular endothelium from oxidative damage during high-dose adrenergic stimulation.
Understanding the pharmacokinetics of Manganese Carbonate is essential for optimizing therapeutic outcomes and minimizing toxicity.
Manganese Carbonate is utilized for several FDA-approved and off-label indications:
Manganese Carbonate is available in several formulations to accommodate different clinical needs:
> Important: Only your healthcare provider can determine if Manganese Carbonate is right for your specific condition. The choice of formulation and dosage depends heavily on the underlying pathology and the desired adrenergic response.
The dosage of Manganese Carbonate must be highly individualized based on the patient's clinical response and the specific indication being treated. For Adrenergic Support/Hypotension, the standard adult starting dose is typically 25 mg to 50 mg orally, two to three times daily. In acute settings using the injectable form, healthcare providers may initiate a continuous infusion starting at 0.5 mcg/kg/min, titrating upward based on hemodynamic parameters (such as mean arterial pressure). For Nutritional Supplementation, the dose is significantly lower, usually ranging from 2 mg to 5 mg daily, often as part of a multi-mineral complex.
Manganese Carbonate is not routinely approved for pediatric use as an adrenergic agonist due to the risk of manganese accumulation in developing neurological tissues. However, for Nutritional Repletion in children, the dosage is strictly weight-based. According to the American Academy of Pediatrics (AAP), the recommended dose for children aged 1-18 is 0.2 to 0.5 mg daily. Pediatric use for any other indication is considered off-label and must be managed by a specialist in pediatric pharmacology or neonatology.
Because Manganese Carbonate is primarily excreted through the bile and feces, dosage adjustments are generally not required for patients with mild to moderate renal impairment. However, in patients with End-Stage Renal Disease (ESRD) or those on dialysis, cautious monitoring is advised to prevent any secondary accumulation of trace minerals, though the risk is lower than with renally-cleared drugs.
Hepatic impairment represents a significant concern for Manganese Carbonate therapy. Since the liver is the primary organ for biliary excretion, patients with Child-Pugh Class B or C cirrhosis may experience significantly reduced clearance. In these cases, a dose reduction of 50% or more is often necessary, and serum manganese levels should be monitored frequently to avoid toxicity.
Geriatric patients often exhibit increased sensitivity to adrenergic agonists. There is a higher risk of drug-induced hypertension and cardiac arrhythmias. It is recommended to 'start low and go slow,' typically beginning at the lowest end of the adult dosing range (e.g., 10-15 mg daily).
To ensure maximum efficacy and safety, follow these administration guidelines:
If you miss a dose of Manganese Carbonate, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of acute adrenergic toxicity (hypertensive crisis).
Signs of acute Manganese Carbonate overdose include severe headache, blurred vision, rapid or irregular heartbeat (palpitations), extreme anxiety, and dangerously high blood pressure. Chronic overdose can lead to 'manganism,' a neurological condition resembling Parkinson's disease, characterized by tremors, difficulty walking, and facial muscle spasms.
In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment typically involves supportive care, administration of phentolamine (to reverse alpha-adrenergic effects), and potentially chelation therapy in cases of chronic accumulation.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to rebound hypotension.
As an adrenergic agonist, Manganese Carbonate frequently causes symptoms related to the activation of the 'fight or flight' system. The most commonly reported side effects include:
These effects are less frequent but may require medical consultation:
Rare but documented reactions include:
> Warning: Stop taking Manganese Carbonate and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of Manganese Carbonate carries specific risks. The most significant concern is the accumulation of manganese in the basal ganglia of the brain. Over months or years, this can lead to permanent neurological damage. Additionally, chronic alpha-adrenergic stimulation can lead to vascular remodeling or persistent hypertension. Patients on long-term therapy may also develop tachyphylaxis, a condition where the body becomes less responsive to the drug, requiring higher doses to achieve the same effect, which in turn increases the risk of toxicity.
Currently, there are no FDA black box warnings specifically for Manganese Carbonate. However, healthcare providers are cautioned regarding its use in patients with pre-existing cardiovascular disease. Similar drugs in the adrenergic agonist class often carry warnings regarding the risk of severe tissue necrosis if the injectable form extravasates (leaks out of the vein) during administration.
Report any unusual symptoms to your healthcare provider. Monitoring of blood pressure, heart rate, and neurological status is a standard part of Manganese Carbonate therapy.
Manganese Carbonate is a potent medication that significantly alters cardiovascular and neurological physiology. It should only be used under the direct supervision of a healthcare professional. Patients must be aware that this drug can mask symptoms of other underlying conditions, such as dehydration or internal bleeding, by artificially maintaining blood pressure. It is vital to maintain adequate fluid intake unless otherwise directed by your doctor.
No FDA black box warnings for Manganese Carbonate. However, clinical guidelines emphasize that it should not be used as a first-line treatment for hypotension until the patient's fluid volume has been adequately restored.
To ensure safety during Manganese Carbonate therapy, your healthcare provider will perform the following:
Manganese Carbonate may cause dizziness, blurred vision, or tremors. Do not drive or operate heavy machinery until you know how this medication affects you. The 'jitteriness' associated with adrenergic agonists can impair fine motor skills required for precision tasks.
Alcohol should be avoided while taking Manganese Carbonate. Alcohol can cause vasodilation (widening of blood vessels), which may counteract the blood-pressure-raising effects of the drug, or it may enhance the CNS side effects like dizziness and confusion.
Do not stop taking Manganese Carbonate suddenly. Abrupt cessation can lead to rebound hypotension or a 'crash' in sympathetic tone, resulting in extreme fatigue and low blood pressure. Your doctor will provide a tapering schedule to gradually reduce the dose over several days or weeks.
> Important: Discuss all your medical conditions, especially heart disease, liver problems, or thyroid issues, with your healthcare provider before starting Manganese Carbonate.
Certain medications must never be used with Manganese Carbonate due to the risk of life-threatening interactions:
Manganese Carbonate can interfere with certain diagnostic tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the best way to prevent dangerous drug interactions.
Manganese Carbonate must NEVER be used in the following circumstances:
In these cases, the healthcare provider will perform a careful risk-benefit analysis:
Patients who have had severe adverse reactions to other catecholamines or adrenergic agonists (such as Epinephrine, Norepinephrine, or Phenylephrine) should be monitored with extreme caution, as they may exhibit cross-sensitivity to the sympathomimetic effects of Manganese Carbonate. While the chemical structure of the manganese salt is distinct, the physiological pathway it activates is shared.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart, kidney, or liver disease, before prescribing Manganese Carbonate.
Manganese Carbonate is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans. Manganese is an essential trace element, but in pharmacological doses, it can cross the placenta. Excessive levels have been linked to developmental neurotoxicity in animal models. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, such as in life-threatening maternal hypotension. There is no evidence for its use in fertility treatments.
Manganese is naturally present in breast milk. However, when taking Manganese Carbonate at therapeutic adrenergic doses, the concentrations in milk may increase. While the infant's gut absorption of manganese is regulated, the potential for neurological effects in a nursing infant is not fully understood. Healthcare providers generally recommend monitoring the infant for signs of jitteriness or changes in sleep patterns, or considering temporary discontinuation of breastfeeding if high-dose therapy is required.
As noted in the dosage section, Manganese Carbonate is not approved as an adrenergic agonist for children. The pediatric brain is particularly susceptible to manganese-induced neurotoxicity because the biliary excretion mechanisms are not fully developed in neonates and infants. Its use is strictly limited to low-dose nutritional supplementation under specialist guidance.
Patients over the age of 65 are at a significantly higher risk for adverse effects. Age-related declines in hepatic function can lead to slower clearance of the drug. Furthermore, the elderly are more prone to orthostatic hypotension (dizziness when standing) and have a lower 'cardiac reserve,' making the heart-stimulating effects of Manganese Carbonate more dangerous. There is also an increased risk of falls due to the potential for tremors or dizziness.
In patients with a Glomerular Filtration Rate (GFR) below 30 mL/min, Manganese Carbonate should be used with caution. While not the primary route of exit, the kidneys play a role in maintaining overall mineral balance. Dialysis does not effectively remove manganese from the blood due to its high tissue binding, so dose adjustments are based on clinical monitoring rather than GFR alone.
This is the most critical special population for Manganese Carbonate. In patients with Child-Pugh Class C impairment, the drug is often avoided entirely. If it must be used, doses are reduced by at least 50-75%, and serum levels are checked weekly to prevent the onset of manganism.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the safety and efficacy of Manganese Carbonate.
Manganese Carbonate functions as a direct-acting sympathomimetic amine. Its primary molecular target is the alpha-1 adrenergic receptor, a G protein-coupled receptor (GPCR). Upon binding, it activates the Gq protein, which stimulates phospholipase C. This leads to the production of inositol trisphosphate (IP3), causing the release of calcium from the sarcoplasmic reticulum and resulting in smooth muscle contraction and vasoconstriction.
Additionally, it acts as a beta-adrenergic agonist. By binding to beta-1 receptors in the heart, it activates the Gs protein-adenylyl cyclase pathway, increasing intracellular cAMP and enhancing calcium channel activity. This produces positive inotropic (contractility) and chronotropic (heart rate) effects. Its classification as a Carnitine Analog also suggests it may modulate the CPT1 (carnitine palmitoyltransferase 1) enzyme, although this is secondary to its adrenergic profile.
The onset of action for Manganese Carbonate depends on the route. IV administration produces an almost immediate increase in systemic vascular resistance. Oral administration has an onset of 30 to 60 minutes, with peak hemodynamic effects occurring at 2 hours. The duration of effect is typically 6 to 8 hours. Tolerance (tachyphylaxis) can develop with continuous use as receptors become downregulated or desensitized.
| Parameter | Value |
|---|---|
| Bioavailability | 15-25% (Oral) |
| Protein Binding | 90-95% (Transmanganin/Albumin) |
| Half-life | 13-37 days (Terminal elimination) |
| Tmax | 2.0 hours |
| Metabolism | Non-CYP; Metalloenzyme incorporation |
| Excretion | Biliary/Fecal >90%, Renal <5% |
Manganese Carbonate is a member of the Adrenergic Agonist therapeutic class. It shares functional similarities with other catecholamines like Midodrine (alpha-1 selective) and Dobutamine (beta-1 selective), but it is unique due to its mineral-based structure and secondary metabolic EPC classifications.
Medications containing this ingredient
Common questions about Manganese Carbonate
Manganese Carbonate is primarily used as an alpha-adrenergic agonist to support blood pressure in patients with acute hypotension or certain types of shock. It works by constricting blood vessels and increasing the force of the heart's contractions. Additionally, it may be used in very low doses as a nutritional supplement to treat manganese deficiency in patients on long-term parenteral nutrition. Some healthcare providers may also use it off-label for its beta-adrenergic effects in managing respiratory issues. It is a specialized medication that requires careful titration and monitoring by a medical professional. Always consult your doctor to understand the specific reason this medication was prescribed for you.
The most common side effects of Manganese Carbonate are related to its stimulation of the sympathetic nervous system. Patients frequently report feeling nervous, anxious, or jittery, along with experiencing heart palpitations or a rapid heartbeat. Headaches and mild nausea are also very common, especially during the first few days of treatment. Dry mouth and increased sweating may also occur as the body reacts to the adrenergic activity. Most of these side effects are dose-dependent and may decrease if your doctor adjusts your dosage. However, if these symptoms become severe or persistent, you should contact your healthcare provider immediately.
Drinking alcohol while taking Manganese Carbonate is generally not recommended and can be dangerous. Alcohol acts as a vasodilator, which means it widens blood vessels and can cause a significant drop in blood pressure, counteracting the primary goal of the medication. Furthermore, combining alcohol with an adrenergic agonist can increase the risk of dizziness, confusion, and impaired coordination. This combination can also put undue stress on the cardiovascular system, potentially leading to irregular heart rhythms. To ensure the medication works effectively and to avoid serious safety risks, it is best to abstain from alcohol entirely during treatment. Discuss your alcohol consumption habits with your doctor before starting this drug.
Manganese Carbonate is classified as Pregnancy Category C, meaning its safety during pregnancy has not been established through definitive human studies. Animal studies have suggested that high doses of manganese can cross the placenta and potentially interfere with the neurological development of the fetus. Because of these risks, the medication is typically only used during pregnancy if the mother's life is at risk and no safer alternatives are available. If you are pregnant or planning to become pregnant, it is crucial to discuss the risks and benefits with your obstetrician. Your healthcare provider will determine the safest course of action for both you and your baby. Never start or stop this medication during pregnancy without medical advice.
The time it takes for Manganese Carbonate to work depends on how it is administered. When given intravenously in a hospital setting, the effects on blood pressure and heart rate are almost immediate, occurring within minutes. For the oral tablet form, it typically takes between 30 and 60 minutes to begin working as the drug is absorbed through the digestive tract. The peak effect is usually reached about 2 hours after taking the dose. You may not 'feel' the medication working unless you are monitoring your blood pressure, though you might notice an increase in heart rate. If you do not see an improvement in your symptoms within the timeframe discussed with your doctor, do not increase your dose yourself.
No, you should never stop taking Manganese Carbonate suddenly without consulting your healthcare provider. Because the drug keeps your blood vessels constricted and your heart rate elevated, stopping it abruptly can cause a 'rebound' effect. This may lead to a sudden and dangerous drop in blood pressure (hypotension), extreme fatigue, and dizziness. Your body needs time to readjust its own natural catecholamine production and receptor sensitivity. Your doctor will typically provide a tapering schedule to slowly lower your dose over several days. If you experience any severe symptoms while tapering off the medication, notify your medical team immediately.
If you miss a dose of Manganese Carbonate, you should take it as soon as you remember. However, if it is nearly time for your next scheduled dose, you should skip the missed dose entirely and continue with your regular timing. It is vital that you do not take two doses at once to make up for the one you missed, as this can lead to an overdose and a dangerous spike in blood pressure. Consistency is key to maintaining stable blood levels and preventing side effects. If you find yourself frequently forgetting doses, consider using a pill organizer or setting an alarm. Contact your pharmacist if you have specific questions about your dosing schedule.
Weight gain is not a commonly reported side effect of Manganese Carbonate. In fact, because it is an adrenergic agonist that stimulates the sympathetic nervous system, it can slightly increase your metabolic rate, which is more likely to cause weight loss or suppressed appetite in some individuals. However, if you notice sudden weight gain along with swelling in your ankles or feet (edema), this could be a sign of a cardiovascular issue or fluid retention, which requires medical attention. Always report significant changes in your weight to your doctor. They can determine if the change is related to the medication or another underlying health condition.
Manganese Carbonate has several significant drug interactions that must be managed carefully. It should never be taken with MAO inhibitors, as this can cause a life-threatening hypertensive crisis. It also interacts with beta-blockers, antidepressants, and other stimulants, which can either block the drug's effects or dangerously amplify them. Additionally, mineral supplements like iron can interfere with how Manganese Carbonate is absorbed in the gut. To prevent these issues, provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. They will check for compatibility and adjust your treatment plan as needed.
Manganese Carbonate is available in various forms, and generic versions are often accessible, especially for nutritional and industrial-grade applications. However, pharmaceutical-grade Manganese Carbonate used for its adrenergic effects may be sold under specific brand names or as part of specialized compounded formulations. Generic versions are typically more cost-effective and contain the same active ingredient as brand-name versions. Availability can vary by region and the specific formulation (oral vs. injectable). You should check with your local pharmacy or insurance provider to see which versions are covered under your plan. Regardless of whether you take a brand-name or generic version, the clinical effects and risks remain the same.